Edina Sinanovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5641949/publications.pdf

Version: 2024-02-01

567281 477307 33 906 15 29 citations h-index g-index papers 34 34 34 1445 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health, 2015, 3, e450-e457.	6.3	179
2	The economic burden of TB diagnosis and treatment in South Africa. Social Science and Medicine, 2015, 130, 42-50.	3.8	122
3	Using Topâ€down and Bottomâ€up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. Health Economics (United Kingdom), 2016, 25, 53-66.	1.7	74
4	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. The Lancet Global Health, 2017, 5, e710-e719.	6.3	53
5	The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine, 2009, 27, 6196-6202.	3.8	47
6	Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1871-1879.	3.0	41
7	Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis– a systematic review of global literature with focus on South Africa. Health and Quality of Life Outcomes, 2016, 14, 42.	2.4	40
8	Health-related quality of life in South African patients with pulmonary tuberculosis. PLoS ONE, 2017, 12, e0174605.	2.5	38
9	Cost per patient of treatment for rifampicinâ€resistant tuberculosis in a communityâ€based programme in Khayelitsha, South Africa. Tropical Medicine and International Health, 2015, 20, 1337-1345.	2.3	31
10	Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa. , 2006, 4, 11 .		30
11	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. PLoS ONE, 2017, 12, e0181519.	2.5	28
12	Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infectious Diseases, 2016, 16, 593.	2.9	23
13	Association between Health-Related Quality of Life and Medication Adherence in Pulmonary Tuberculosis in South Africa. Frontiers in Pharmacology, 2017, 8, 919.	3.5	19
14	How to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis – Designing a Prospective Observational Study in South Africa. Frontiers in Pharmacology, 2016, 7, 125.	3.5	18
15	Sharing the burden of TB/HIV? Costs and financing of public–private partnerships for tuberculosis treatment in South Africa. Tropical Medicine and International Health, 2006, 11, 1466-1474.	2.3	17
16	Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Applied Health Economics and Health Policy, 2018, 16, 43-54.	2.1	17
17	National tuberculosis spending efficiency and its associated factors in 121 low-income and middle-income countries, 2010–19: a data envelopment and stochastic frontier analysis. The Lancet Global Health, 2022, 10, e649-e660.	6.3	14
18	The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa. PLoS ONE, 2017, 12, e0174615.	2.5	13

#	Article	IF	CITATIONS
19	Developing the Global Health Cost Consortium Unit Cost Study Repository for HIV and TB: methodology and lessons learned. African Journal of AIDS Research, 2019, 18, 263-276.	0.9	13
20	The motivations for participation in public–private partnerships for the provision of tuberculosis treatment in South Africa. Global Public Health, 2010, 5, 479-492.	2.0	12
21	The costs of accessing abortion in South Africa: women's costs associated with second-trimester abortion services in Western Cape Province. Contraception, 2015, 92, 339-344.	1.5	12
22	Accessing medical and surgical first-trimester abortion services: women's experiences and costs from an operations research study in KwaZulu-Natal Province, South Africa. Contraception, 2017, 96, 72-80.	1.5	12
23	The costs and cost effectiveness of providing second-trimester medical and surgical safe abortion services in Western Cape Province, South Africa. PLoS ONE, 2018, 13, e0197485.	2.5	11
24	A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology. Pharmacoeconomics, 2020, 38, 819-837.	3.3	8
25	Doing more for less: identifying opportunities to expand public sector access to safe abortion in South Africa through budget impact analysis. Contraception, 2018, 97, 167-176.	1.5	6
26	Cost of managing severe cutaneous adverse drug reactions to firstâ€line tuberculosis therapy in South Africa. Tropical Medicine and International Health, 2019, 24, 994-1002.	2.3	5
27	The cost and utilisation patterns of a pilot sign language interpreter service for primary health care services in South Africa. PLoS ONE, 2017, 12, e0189983.	2.5	5
28	Comparing the Application of CEA and BCA to Tuberculosis Control Interventions in SouthÂAfrica. Journal of Benefit-Cost Analysis, 2019, 10, 132-153.	1.2	4
29	Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis. PLoS ONE, 2021, 16, e0251547.	2.5	4
30	Rapid point-of-care testing for genital tract inflammatory cytokine biomarkers to diagnose asymptomatic sexually transmitted infections and bacterial vaginosis in women. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	1.7	4
31	Provider―and patient―evel costs associated with providing antiretroviral therapy during the postpartum phase to women living with HIV in South Africa: A cost comparison of three postpartum models of care. Tropical Medicine and International Health, 2020, 25, 1553-1567.	2.3	3
32	Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa. Cost Effectiveness and Resource Allocation, 2014, 12, 20.	1.5	2
33	A cost comparison analysis of paediatric intermediate care in a tertiary hospital and an intermediate care facility in Cape Town, South Africa. PLoS ONE, 2019, 14, e0214492.	2.5	1